Back to Search
SUNDARARAJAN RAJKUMAR, M.D.
M.D.
Hematology (Internal Medicine) Physician
NPI: 1548240914IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
37218(MN)
Education
OTHER
Class of 1989
Research & Publications (20)
Front-line treatment in younger patients with multiple myeloma.
PMID 19389495·Semin Hematol·2009
6-review
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
PMID 18362366·J Clin Oncol·2008
3-trial
Controversies regarding the use of dexamethasone in patients with multiple myeloma.
PMID 18347560·Clin Adv Hematol Oncol·2008
8-other
Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
PMID 18070712·Best Pract Res Clin Haematol·2007
6-review
Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
PMID 17947482·Clin Cancer Res·2007
3-trial
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
PMID 17367905·Blood Rev·2007
6-review
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
PMID 16365178·J Clin Oncol·2006
3-trial
Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment.
PMID 16706268·Mayo Clin Proc·2006
6-review
MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
PMID 16304401·Hematology Am Soc Hematol Educ Program·2005
8-other
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
PMID 16118317·Blood·2005
3-trial
Conventional therapy and approach to management.
PMID 16026739·Best Pract Res Clin Haematol·2005
6-review
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.
PMID 15855274·Blood·2005
8-other
Proteasome inhibition as a novel therapeutic target in human cancer.
PMID 15659509·J Clin Oncol·2005
6-review
Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
PMID 15491291·Br J Haematol·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1548240914
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile